PNEUMOCOCCAL CONJUGATE VACCINES

被引:23
|
作者
PEETERS, CCAM [1 ]
TENBERGENMEEKES, AM [1 ]
HAAGMANS, B [1 ]
EVENBERG, D [1 ]
POOLMAN, JT [1 ]
ZEGERS, BJM [1 ]
RIJKERS, GT [1 ]
机构
[1] NATL INST PUBL HLTH & ENVIRONM PROTECT, BACTERIAL VACCINE DEV & PATHOGENESIS RES UNIT, BILTHOVEN, NETHERLANDS
关键词
PNEUMOCOCCAL POLYSACCHARIDE; CONJUGATE VACCINE; ANTIBODY SYNTHESIS; TOLERANCE;
D O I
10.1016/0165-2478(91)90036-A
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein. In general, polysaccharide conjugates induced higher anti-PS4 IgG antibody titers than oligosaccharide conjugates. Conjugates with the highest amount of incorporated protein were the most immunogenic. The response to conjugated PS4 does show characteristics of a T cell-dependent antibody response, in terms of both isotype distribution and induction of immunological memory. Repeated immunization with high doses of PS4TT conjugate resulted in a virtually negative anti-PS4 IgG response, suggestive of the induction of high dose tolerance.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [41] IMMUNOGENICITY OF TWO PNEUMOCOCCAL CONJUGATE VACCINES • 766
    Eugene D Shapiro
    Sheldon L Kaplan
    Mark C Steinhoff
    Edward O Mason
    Robert S Daum
    [J]. Pediatric Research, 1997, 41 (Suppl 4) : 130 - 130
  • [42] Impact of conjugate pneumococcal vaccines on antibiotic resistance
    Dagan, Ron
    Klugman, Keith P.
    [J]. LANCET INFECTIOUS DISEASES, 2008, 8 (12): : 785 - 795
  • [43] Pneumococcal conjugate vaccines in different settings reply
    Hanage, William P.
    Lewnard, Joseph A.
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (12): : 1284 - 1284
  • [44] Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines
    Koutouzis, Emmanouil I.
    Michos, Athanasios
    Koutouzi, Foteini I.
    Chatzichristou, Panagiota
    Parpounas, Konstantinos
    Georgaki, Angeliki
    Theodoridou, Maria
    Tsakris, Athanasios
    Syriopoulou, Vassiliki P.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (03) : 292 - 296
  • [45] The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children
    Pelton, SI
    Klein, JO
    [J]. PEDIATRICS, 2002, 110 (04) : 805 - 814
  • [46] Epidemiology of pneumococcal diseases in Spain after the introduction of pneumococcal conjugate vaccines
    Maria Marimon, Jose
    Ardanuy, Carmen
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2021, 39 (03): : 142 - 150
  • [47] Can hexavalent vaccines be simultaneously administered with pneumococcal or meningococcal conjugate vaccines?
    Tozzi, Alberto E.
    Azzari, Chiara
    Bartolozzi, Giorgio
    Esposito, Susanna
    Fara, Gaetano Maria
    Lo Giudice, Milena
    [J]. HUMAN VACCINES, 2007, 3 (06): : 252 - 259
  • [48] Budget impact analysis of pneumococcal conjugate vaccines in Colombia
    Gomez, Jorge
    Moreno, Luz Elena
    Constenla, Dagna
    Caceres, Diana
    Rodriguez, Edisson
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 255 - 263
  • [49] New vaccines pneumococcal conjugate: touring her success
    Zamorano, Juanita
    [J]. MEDWAVE, 2010, 10 (02):
  • [50] Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe
    Rodgers, Gail L.
    Whitney, Cynthia G.
    Klugman, Keith P.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 224 : S352 - S359